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Lysyl oxidase-like 2 inhibition 
ameliorates glomerulosclerosis 
and albuminuria in diabetic 
nephropathy
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Diabetic nephropathy is characterised by the excessive amount of extracellular matrix in glomeruli and 
tubulointerstitial space. Lysyl oxidase-like 2 (LOXL2) is elevated in renal fibrosis and known to play key 
roles in ECM stabilisation by facilitating collagen cross-links, epithelial to mesenchymal transition and 
myofibroblast activation. Thus, targeting LOXL2 may prove to be a useful strategy to prevent diabetic 
nephropathy. We explored the renoprotective effect of a selective small molecule LOXL2 inhibitor 
(PXS-S2B) in a streptozotocin-induced diabetes model. Diabetic mice were treated with PXS-S2B for 
24 weeks and outcomes compared with untreated diabetic mice and with telmisartan treated animals 
as comparator of current standard of care. Diabetic mice had albuminuria, higher glomerulosclerosis 
scores, upregulation of fibrosis markers and increased renal cortical LOXL2 expression. Treatment 
with PXS-S2B reduced albuminuria and ameliorated glomerulosclerosis. This was associated with 
reduced expression of glomerular fibronectin and tubulointerstitial collagen I. The renoprotective 
effects of both PXS-S2B and telmisartan were more marked in the glomerular compartment than in the 
tubulointerstitial space. The study reveals that LOXL2 inhibition was beneficial in preserving glomerular 
structure and function. Thus, LOXL2 may be a potential therapeutic target in diabetic nephropathy.
Diabetic nephropathy, clinically characterised by increasing proteinuria and an eventual decline in glomerular 
filtration rate, is the leading cause of end-stage kidney disease (ESKD) worldwide and the incidence is expected 
to rise1. Current treatments of diabetic nephropathy are limited to blockade of the renin-angiotensin-aldosterone 
system (RAAS). However, despite RAAS blockade a significant residual risk of progression to ESKD remains2,3. 
In early stages the histopathology is characterised by glomerular basement membrane (GBM) thickening, often 
paralleled by tubular basement membrane thickening, followed by mesangial expansion, which can lead to nodu-
lar and diffuse glomerulosclerosis. Other features of diabetic nephropathy include arteriolar hyalinosis, atrophic 
tubules and tubulointerstitial fibrosis as a late manifestation4. While the various lesions of diabetic nephropathy 
progress at varying rates, many of the characteristic manifestations are a consequence of extracellular matrix 
(ECM) accumulation ultimately leading to renal fibrosis.
The extracellular matrix in healthy tissues is a scaffold to maintain tissue integrity and a reservoir for media-
tors of cell signaling and cell growth5. The ECM is a highly dynamic structure that is in constant flux of remod-
eling through matrix synthesis and degradation. Dysregulation of this tightly regulated balance will lead to 
exaggerated matrix deposition and an exacerbation of disease progression. Indeed, it has been reported that a 
fibrotic ECM can perpetuate fibrogenesis by stimulating myofibroblasts to synthesise further ECM proteins in a 
positive feedback loop6. In renal fibrosis ECM becomes the principal component replacing normal renal paren-
chyma. Targeting mediators of the dysregulated ECM remodeling process may offer a promising therapeutic 
opportunity for kidney fibrosis.
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The lysyl oxidase family is a group of amine oxidases that play a crucial role in ECM remodeling and are 
foremost known for their ability to promote covalent cross-linking of collagen in the ECM7. The five mem-
bers of the lysyl oxidase family include the originally identified lysyl oxidase (LOX) and four lysyl oxidase-like 
proteins (LOXL1, LOXL2, LOXL3, LOXL4) that share sequence homology and have similar function. These 
copper-dependent enzymes catalyze the oxidation of lysine residues in collagen and elastin to highly reactive 
aldehydes, which spontaneously condense with other lysyl oxidase-derived aldehydes or unmodified lysine res-
idues to generate intermolecular cross-links between the collagen fibers. The cross-linked collagen renders the 
ECM resistant against proteolytic enzymes and the resulting tissue stiffness is a prerequisite for the activation 
of myofibroblasts8. In addition to its extracellular function of collagen cross-linking, LOXL2 in particular is 
involved in transcriptional regulation by promoting epithelial-to mesenchymal transition (EMT)9. LOXL2 is a 
downstream-target of hypoxia-inducible factor-1α (HIF-1α)10 and is induced by transforming growth factor 
beta (TGFβ)11, both of which are key players in the pathogenesis of tissue fibrosis. Indeed, an increase of LOXL2 
expression has been extensively investigated in fibrotic diseases of lung12,13 and liver13,14. However its role in renal 
fibrosis is limited to a few studies10,15 and has not been explored as a treatment target in kidney disease. PXS-S2B 
is a novel haloallylamine-derived, small-molecule LOXL2 inhibitor with oral bioavailability, high potency and 
strong selectivity for LOXL2. The compound’s selectivity for LOXL2 and its characteristics have been previously 
published16. The present study aims to explore the role of LOXL2 in a renal fibrosis model of diabetic nephropathy 
and examined the therapeutic potential of PXS-S2B as a renoprotective small molecule.
Results
Clinical characteristics. Endothelial nitric oxide synthase knockout (eNOS−/−) mice were chosen due to 
their ability to develop accelerated renal injury after streptozotocin (STZ) induced diabetes17. The clinical char-
acteristics of the groups are summarised in Table 1. STZ treated mice had elevated fasting blood glucose levels 
(BGL) (P < 0.01 vs. control (Ctrl)), lower body weight and higher glycated haemoglobin (HbA1c) (P < 0.01 vs. 
Ctrl) consistent with established diabetes. There was no significant difference in HbA1c levels between the four 
diabetic groups: diabetes (DM), diabetes treated with the LOXL2 inhibitor PXS-S2B (DM + LOXL2i), diabe-
tes treated with telmisartan (DM + Telmi) and diabetes treated with both drugs (DM + LOXL2i + Telmi). Daily 
treatment with PXS-S2B over the 24-week period was well tolerated with no adverse drug effects noted, in par-
ticular no histological damage in liver, heart or lung (data not shown).
Increased renal LOXL2 expression in mice. In order to confirm the expression of LOXL2 upon disease 
induction, kidneys were stained with LOXL2 antibody. LOXL2 immunohistochemistry had a distinct staining 
pattern with a predominantly tubular localisation. Diabetic mice had significantly increased staining in the renal 
cortex which was most pronounced in areas of tubular atrophy and damage (P < 0.05 vs. Ctrl, Fig. 1B). Most 
glomeruli of control mice did not stain for LOXL2 (Fig. 1E) whereas the diabetic mice had increased numbers 
of glomeruli with positive staining (Fig. 1F). Specifically mice with average fasting blood glucose >24 mmol/L 
had glomeruli with very strong LOXL2 immunostaining even in areas where tubular staining was minimal 
(Fig. 1H). Although there was strong staining along the corticomedullary junction, it did not differ between con-
trol (Fig. 1D) and diabetic animals (Fig. 1E).
LOXL2 inhibition reduces albuminuria in diabetic mice. Albuminuria reflects damage to the glo-
merular filtration barrier and is the earliest sign of diabetic nephropathy. The excess ultrafiltered protein load 
then perpetuates kidney disease progression through multiple pathways including induction of chemokine and 
cytokine expression leading to inflammatory cell infiltration and fibrogenesis18. The urinary albumin to creati-
nine ratio obtained in the final week was nearly fourfold increased in untreated diabetic mice to 813 ± 194 μg/mg 
vs. 213 ± 14 μg/mg in the control group (P < 0.01 vs. Ctrl). Diabetic mice treated with PXS-S2B had significant 
reduction of albuminuria (418 ± 108 μg/mg, P < 0.05 vs. DM). Treatment with Telmisartan and the combination 
treatment (LOXL2i + Telmi) resulted in further reduction of albuminuria (168 ± 19 μg/mg, P < 0.01 vs. DM and 
150 ± 41 μg/mg, P < 0.01 vs. DM respectively, Fig. 2).
LOXL2 inhibition reduces glomerulosclerosis. As diabetic nephropathy progresses excess ECM accu-
mulates in the mesangium leading to glomerulosclerosis. The untreated diabetic mice (Fig. 3B) developed signifi-
cant glomerulosclerosis compared to the control group (P < 0.01 vs. Ctrl, Fig. 3A). Diabetic mice treated with the 
LOXL2 inhibitor had significant reduction in the glomerulosclerosis score (P < 0.05 vs. DM, Fig. 3C), whereas 
the reduction in the telmisartan group was statistically not significant (Fig. 3D). The glomerulosclerosis index 
was further reduced when the treatment with the LOXL2 inhibitor and telmisartan was combined (p < 0.01, 
Fig. 3E). In contrast to glomerulosclerosis the diabetes induced tubulointerstitial damage was less pronounced. 
n = 5–8 Ctrl DM DM + LOXL2i DM + Telmi DM + LOXL2i + Telmi
Body weight (g) 25.0 ± 0.31 21.5 ± 0.90** 21.5 ± 0.78** 23.1 ± 0.62* 22.7 ± 0.57**
Average BGL (mmol/L) 9.7 ± 0.44 20.6 ± 0.40** 23.88 ± 0.72## 26.2 ± 0.50## 24.7 ± 0.65##
HbA1c (%) 4.3 ± 0.05 8.1 ± 0.18** 8.4 ± 0.12** 8.7 ± 0.23** 8.9 ± 0.50**
Table 1. Clinical characteristics of mice. Average fasting BGL over the course of the experiment. Body 
weight and HbA1c were taken at time of sacrifice. Only mice with final HbA1c of ≥7.5% were included in the 
subsequent data analysis. Data are expressed as mean ± SEM of 5–8 mice per group. *P < 0.05 vs. Ctrl, **P < 0.01 
vs. Ctrl, ##P < 0.01 vs. DM.
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This was characterised by dilated tubules and flattened tubular epithelial cells with minor tubulointerstitial ECM 
deposition on Masson Trichrome stained paraffin sections. There was no difference seen in the treated animals in 
comparison to untreated diabetic mice (Fig. 3G).
LOXL2 inhibition reduces fibronectin expression in diabetic glomeruli. Fibronectin, an adhesive 
glycoprotein activates integrins, functions as fibroblast chemoattractant and forms a scaffold for the deposition of 
fibrillar collagens. It is one of the first ECM proteins deposited in renal fibrosis5. Immunohistochemical staining 
for cortical fibronectin was increased in diabetic mice (P < 0.01 vs. Ctrl) and was strongly deposited in sclerosed 
glomeruli and to a lesser extent in the tubulointerstitial space. Diabetic mice treated with either PXS-S2B or tel-
misartan had significant reduction in fibronectin mRNA (P < 0.01 vs. DM and P < 0.01 vs. DM respectively) and 
significant reduction in fibronectin immunostaining (P < 0.05 and P < 0.01 vs. DM respectively, Fig. 4).
LOXL2 inhibition reduces tubulointerstitial collagen I. Collagen I is minimally expressed in healthy 
kidneys but is known to increase in renal fibrosis. Similar to fibronectin, it appears in early stages of renal fibrosis5. 
Collagen I immunostaining was significantly increased in diabetic mice and was predominantly localised in the 
tubulointersitital space. (P < 0.05 vs. Ctrl). Treatment with PXS-S2B resulted in a significant reduction in colla-
gen I immunostaining (P < 0.05 vs. DM). Telmisartan treatment similarly resulted in a significant reduction of 
collagen I immunuostaining (P < 0.05 vs. DM), which was not different from control values (Fig. 5). Collagen IV 
protein, the most abundant collagen in healthy kidneys and integral component of tubular and glomerular base-
ment membranes was slighthly upregulated in diabetic kidneys although this did not reach statistical significance. 
There was a trend of reduction after treatment with PXS-S2B and a significant reduction in the telmisartan and in 
the combined treatment group (P < 0.05 vs. DM, P < 0.01 vs DM respectively, Fig. 6).
Figure 1. LOXL2 immunostaining in renal cortices (A–C), corticomedullary junction (D–F) and glomeruli 
(G–I). LOXL2 expression was significantly increased in the renal cortices of diabetic animals (DM) (B) vs. 
control (Ctrl) (A). The medulla had a characteristic staining pattern along the corticomedullary junction 
without significant difference between Ctrl (D) and DM (E). Increased numbers of glomeruli stained positive 
for LOXL2 in DM (H) vs. Ctrl (G). Scale bar = 200 μm. Mean ± SEM, *P < 0.05 vs. Ctrl, n = 5–7.
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Effect of LOXL2 inhibition on myofibroblast activation. De-novo expression of αSMA is a 
marker of myofibroblast activation, which are the principle cells responsible for the excess ECM synthesis19. 
Immunostaining of αSMA was increased in diabetic mice in our model (Fig. 7) with a trend towards reduc-
tion after LOXL2 treatment, although this did not reach statistical significance. αSMA staining was significantly 
reduced in the telmisartan group (P < 0.05 vs. DM) but not in the combined treatment group. The epithelial 
marker E-Cadherin, which is typically downregulated in EMT showed only a trend of reduction in the diabetic 
group not reaching statistical significance (data not shown), which suggests that EMT was not a major contribu-
tor to the myofibroblast pool in the diabetic group in our study.
Discussion
Despite the known involvement of LOXL2 in a variety of processes that affect ECM deposition and enhance 
fibrosis, its role as a potential treatment target in renal fibrosis is not well studied. Using the novel, selective, small 
molecule LOXL2-inhibitor PXS-S2B in a mouse model of diabetic nephropathy we demonstrated both a struc-
tural and functional benefit. Diabetic animals treated with the LOXL2 inhibitor had lower albuminuria and ame-
liorated glomerulosclerosis with reduced cortical ECM markers. These changes were more prominently observed 
in the glomerular compartment than the tubulointerstitial space. We firstly, and to date, uniquely demonstrated 
increased levels of LOXL2 in renal cortices of mice with diabetic nephropathy. The expression pattern of LOXL2 
in focal areas of strong tubular damage as well as de-novo expression in diseased glomeruli suggests its direct 
involvement in the renal fibrosis process. Despite the lack of difference between the diabetic and treated groups 
by Masson Trichrome staining, we demonstrated a significant reduction in fibronectin as well as collagen I with 
a trend towards lower collagen IV, suggestive of reduced tubolointerstitial fibrosis. These findings indicate that 
LOXL2 may be a suitable therapeutic target in diabetic nephropathy.
The induction of renal lysyl oxidases, in particular LOX and LOXL2 has been shown in several kidney disease 
models10,20–22. In Sprague Dawley rats with Adriamycin nephropathy, LOX mRNA was upregulated in glomeruli, 
medulla and whole kidneys early in the disease process and this preceded the development of diffuse fibrotic 
lesions21. Upregulation of LOXL2 was both observed in an experimental model of tubulointerstitial fibrosis by 
unilateral ureteric obstruction (UUO) and in renal biopsies of patients with chronic kidney disease of various 
aetiologies10. Higgins et al. found increased LOXL2 expression in the tubulointerstitial compartment of renal 
biopsies from patients with diabetic nephropathy, IgA nephropathy and hypertensive nephrosclerosis supporting 
the notion that LOXL2 may play a role in the development and progression of diabetic nephropathy and other 
aetiologies of renal fibrosis10.
The present study shows an attenuation of glomerulosclerosis and albuminuria as well as a reduction in 
glomerular fibronectin with the LOXL2 inhibitor treatment, indicating a protective effect in the glomerulus. 
This finding is supported by recent studies, which highlight the role of LOXL2 in the glomerulus. Anazco et al. 
demonstrated in microdissected mouse glomeruli that LOXL2 is the predominant lysyl oxidase and transcripts 
of the other lysyl oxidase family members were expressed at much lower levels. Further, it was demonstrated, 
that immunoreactivity in the glomerulus both localised to the extracellular and to the podocyte’s perinuclear 
compartment suggestive of locally and endogenously produced LOXL2 by podocytes23. High-throughput studies 
from microdissected glomeruli of patients with nephrosclerosis have also reported an increase of LOXL215. By 
Figure 2. Urine albumin/creatinine ratio in control (Ctrl), diabetic (DM) and diabetic mice treated with 
PXS-S2B (DM + LOXL2i) and/or telmisartan (DM + Telmi, DM + LOXL2i + Telmi). Data are expressed as 
mean ± SEM of 5–8 mice per group. **P < 0.01 vs. Ctrl, #P < 0.05 vs. DM, ##P < 0.01 vs. DM.
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Figure 3. LOXL2 inhibition reduced glomerulosclerosis in diabetic mice. Top image shows representative 
images of PAS stained kidney sections for (A) Ctrl, (B) DM, (C) DM + LOXL2i, (D) DM + Telmi, (E) 
DM + LOXL2i + Telmi, scale bar = 50 μm. Bottom image shows Masson trichrome staining for assessment of 
tubulointerstial fibrosis for (A) Ctrl, (B) DM, (C) DM + LOXL2i, (D) DM + Telmi, (E) DM + LOXL2i + Telmi, 
scale bar = 200 μm (F) Glomerulosclerosis index score of 20 glomeruli, mean ± SEM, **P < 0.01 vs. Ctrl, 
#P < 0.05 vs. DM, ##P < 0.01 vs. DM, n = 4–8. (G) Tubulointerstital fibrosis score of 10 non-overlapping sections 
per slide, mean ± SEM.
Figure 4. LOXL2 inhibition reduced fibronectin. Representative photographs for (A) Ctrl, (B) DM, (C) 
DM + LOXL2i, (D) DM + Telmi, (E) DM + LOXL2i + Telmi, scale bar = 50 μm, (F) fibronectin mRNA and  
(G) unmunohistochemistry quantification. Mean ± SEM, **P < 0.01 vs. Ctrl, #P < 0.05 vs. DM, ##P < 0.01 vs. 
DM, n = 5–7.
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demonstrating that LOXL2 inhibition modifies ECM in diseased glomeruli we have strengthened the evidence 
for LOXL2 to be involved in the glomerular disease process.
Hypoxia has well been described to occur in renal fibrosis due to both tubulointerstitial and glomerular cap-
illary rarefaction24. LOXL2 is induced by hypoxia via hypoxia-inducible factor-1 (HIF-1)25. A previous study on 
glomerular podocytes exposed to hypoxic conditions in vitro demonstrated a more than two-fold upregulation 
of LOXL226. Hypoxia is a known fibrogenic stimulus27 and LOXL2 may be the connecting link in perpetuating a 
vicious cycle of microvascular rarefaction, hypoxia and increased ECM synthesis in the glomerulus. The amelio-
ration of glomerulosclerosis and proteinuria in this model by selective LOXL2 inhibition with PXS-S2B appears 
to be an indicator that this vicious cycle can be successfully interrupted.
Fibronectin was predominantly localized in the glomerulus in our study and was reduced after treatment 
with PXS-S2B. Previous studies lend support for the involvement of lysyl oxidases in transcriptional regulation of 
non-collagen ECM proteins such as fibronectin. In vitro stimulation of cancer-associated fibroblasts with recom-
binant LOXL2 significantly increased the expression of fibronectin mRNA8. These stimulated fibroblast cultures 
also demonstrated increased levels of LOXL2 transcripts suggestive of a positive feed-forward loop to further 
Figure 5. Diabetic mice had increased levels of collagen I, which were significantly reduced after treatment 
with the LOXL2 inhibitor. Representative images of collagen I immunostaining for (A) Ctrl, (B) DM, (C) 
DM + LOXL2i, (D) DM + Telmi, (E) DM + LOXL2i + Telmi, scale bar = 50 μm, (F) collagen I mRNA and (G) 
immunohistochemistry quantification. Mean ± SEM, *P < 0.05 vs. Ctrl, #P < 0.05 vs. DM, n = 5–7.
Figure 6. Representative images of collagen IV immunostaining for (A) Ctrl, (B) DM, (C) DM + LOXL2i, (D) 
DM + Telmi, (E) DM + LOXL2i + Telmi, scale bar = 50 μm, (F) collagen I mRNA and (G) immunohistochemistry 
quantification. Mean ± SEM, #P < 0.05 vs. DM, n = 4–7.
www.nature.com/scientificreports/
7SCIeNtIFIC RepoRtS |  (2018) 8:9423  | DOI:10.1038/s41598-018-27462-6
enhance the profibrotic stimulus. Silencing of LOXL2 both in vitro and in vivo decreased fibronectin mRNA28,29 
without affecting the expression of EMT transcription factors Snail and E-Cadherin29.
Additional studies have shown that LOX forms tight complexes with fibronectin, although fibronectin is not 
a direct substrate of LOX’s catalytic domain30. It is becoming more apparent that lysyl oxidases have biological 
roles that go beyond collagen cross-linking however the exact mechanisms by which lysyl oxidases modulate 
fibronectin expression remain to be shown.
In contrast to the glomerular compartment, the treatment effect was less obvious in the tubulointerstitial 
compartment in our study. We observed a reduction in tubulointerstitial collagen I, which is deposited in early 
stages of fibrosis. However, we were unable to identify a significant difference in the tubulointerstitial fibrosis 
score. The tubulointerstitial damage was mainly characterised by tubular atrophy while excess ECM accumulation 
in the diabetic groups was less pronounced. Although the eNOS−/− mouse is to date one of the most acceptable 
rodent models for diabetic nephropathy, the severity of tubulointerstitial fibrosis does not fully resemble that of 
an advanced human diabetic nephropathy17. It is well accepted that the genetic background is important in deter-
mining the degree of tubulointerstitial changes31. The C57BL/6 strain which was the only available genetic back-
ground strain for eNOS−/− mice at the outset of our study is known to be relatively resistant to develop diabetic 
nephropathy whereas mice on a C57BLKS background are more nephropathy-sensitive and also demonstrate 
greater tubulointerstitial fibrosis32. It is conceivable that the beneficial effect of PXS-S2B on ECM modification 
and tubulointerstitial matrix deposition was underestimated in our model and that the actual effect in advanced 
human disease, where tubulointerstitial fibrosis corresponds to decline in GFR is far greater than demonstrated. 
Further studies in chronic disease models with more marked tubulointerstitial fibrosis may be of value.
Myofibroblasts are the key effector cells that synthesise and secrete ECM proteins. The transient recruitment 
and activation of myofibroblasts represents a normal repair response to tissue injury however the persistence 
of myofibroblasts at sites of tissue injury is a hallmark in human fibrotic diseases33. The diabetic mice in this 
model had significantly increased numbers of activated myofibroblasts as evidenced by the elevated levels of renal 
αSMA. Following treatment with PXS-S2B there was a trend towards reduction in αSMA, although this did not 
reach statistical significance and is likely a consequence of the small sample size. EMT of injured tubular epithelial 
cells has been recognised to play a role in diabetic nephropathy and renal fibrosis in general, however the extent 
by which it contributes to the pool of activated myofibroblasts in the kidney is still a topic of intense debate. 
Although studies in cancer biology have demonstrated that LOXL2 is able to regulate EMT via stabilisation of the 
EMT transcription factor Snail9,34, we found no significant reduction in E-Cadherin, which as a primary down-
stream target of Snail is generally repressed in EMT. This finding substantiates the notion that EMT did not play a 
significant role in the activation of myofibroblasts in this model which is in accordance with recent fate mapping 
studies that have demonstrated only a small percentage of myofibroblasts are truly derived via a fully executed 
EMT35.
Previous studies have shown that physical stimuli specifically the matrix stiffness are known to play a role in 
the activation of myofibroblasts36. It has been demonstrated that fibrotic ECM activates fibroblasts to pathologi-
cally remodel the ECM via a positive feedback loop6. Moreover TGFβ is unable to induce myofibroblast activation 
in the absence of a stiff matrix37. We hypothesise that a disruption of cross-linking will invariably reduce matrix 
stiffness and this may reduce the activation of myofibroblasts.
Despite recent advances, the number of studies investigating the role of lysyl oxidases in the kidney is scarce. 
More knowledge has been gained from observations in other fibrotic tissues. LOXL2, in particular was impli-
cated to play a key role in the development of fibrosis in liver13,14 and lung12,13 as well as in cancer progression 
where a fibrotic microenvironment facilitates motility and invasion38. Barry-Hamilton et al. detected increased 
LOXL2 at the fibrotic disease interface in human liver fibrosis and idiopathic pulmonary fibrosis. Treatment with 
Figure 7. Representative images of αSMA immunostaining. (A) Ctrl, (B) DM, (C) DM + LOXL2i, (D) 
DM + Telmi, (E) DM + LOXL2i + Telmi, scale bar = 50 μm. *P < 0.05 vs. Ctrl, #P < 0.05 vs. DM, n = 5–8.
www.nature.com/scientificreports/
8SCIeNtIFIC RepoRtS |  (2018) 8:9423  | DOI:10.1038/s41598-018-27462-6
a monoclonal LOXL2 antibody (AB0024) in murine models of liver and lung fibrosis resulted in amelioration 
of histological fibrosis scores, substantial reduction in collagen and αSMA positive fibroblasts13. Compared to 
LOXL2 inhibition, treatment with a monoclonal antibody targeting specifically LOX did not alter liver fibrosis 
scores13, suggesting LOXL2 to be the superior target of antifibrotic therapy in these organs.
Taken together the findings obtained from this study indicate an upregulation of LOXL2 in a mouse model 
of diabetic nephropathy and beneficial effect of LOXL2 inhibition on the structure and barrier function of the 
glomerulus. The inhibition of LOXL2 with a novel small molecule LOXL2 inhibitior was well tolerated and lead to 
the amelioration of glomerulosclerosis and proteinuria. The known multifaceted action of LOXL2 on ECM syn-
thesis involving cross-linking of collagens, myofibroblast activation and stimulation of increased matrix products 
makes it a promising target in diabetic kidney fibrosis and possibly renal fibrosis of other aetiologies.
Methods
Animal Model. Male eNOS knockout mice (eNOS−/−) on C57BL/6 background were purchased from 
Jackson laboratory, USA. Mice were housed in single cages at 22 ± 1 °C with a 12/12 hr light dark cycle with free 
access to standard chow and drinking water. Diabetes mellitus was induced by intraperitoneal streptozotocin 
(STZ) injection (55 mg/kg diluted in sterile 10 mM citrate buffer, pH4.5 daily for 5 consecutive days) at 6–9 weeks 
of age. A group of mice receiving citrate buffer alone served as the non-diabetic controls. Blood glucose level 
(BGL) was determined by tail vein blood collection using an Accu-chek glucometer (Roche Diagnostics) after a 
6 hour daytime fast. Mice with BGL >16 mmol/L two weeks post STZ injection were considered diabetic. Fasting 
BGLs were tested at least fortnightly. Long lasting insulin was administered as required (Insulin Glargine, Sanofi 
Aventis, Australia) if blood glucose levels exceeded 28 mmol/L and fasting glucose was again checked within one 
week39. The study was approved by the Animal Research Ethics Committee of the Royal North Shore Hospital 
(protocol number 1309-003 A) and was carried out according to the Australian Code of Practice for the Care and 
Use of Animals for Scientific Purposes. Animals were anaesthetised using short inhalational anaesthesia with 2% 
isoflurane for minor procedures and were euthanised under 2% isoflurane anaesthesia using cardiac puncture 
terminally.
Experimental Design. PXS-S2B, a small-molecule selective LOXL2 inhibitor (kindly provided by 
Pharmaxis Ltd., Frenchs Forest, Australia) was administered by daily oral gavage (10 mg/kg) through a flexi-
ble plastic gavage tube (Instech laboratories, USA). Telmisartan (Santa Cruz, CA, USA) was mixed in drink-
ing water (2 mg/kg/d, pH7.4) as a comparative limb of current best practice. The dose chosen is not known to 
have any blood pressure lowering effect40. Animals were divided into the following groups: 1) Control (Ctrl), 2) 
Diabetic (DM), 3) Diabetic receiving the LOXL2 inhibitor (DM + LOXL2i), 4) Diabetic receiving Telmisartan 
(DM + Telmi), 5) Diabetic receiving the LOXL2 inhibitor and Telmisartan (DM + Telmi + LOXL2i). Treatment 
was carried out for 24 weeks from diagnosis of diabetes. At the time of culling, kidneys were perfused in ice-cold 
PBS before harvest and snap frozen in liquid nitrogen or fixed in 10% neutral buffered formalin for 24 hours prior 
paraffin embedding.
Compound Characteristics. PXS-S2B is a hallallylamine-derived, mechanism-based inhibitor amine oxi-
dase inhibitor with high oral bioavailability. It distributes well into tissues and forms PXS-S2A, which has high 
selectivity for LOXL2 over LOX. It is characterised by good plasma stability and moderate plasma protein bind-
ing. The compound characteristics have been described in detail previously16.
Physiological Parameters. Body weight was obtained monthly. Urine was collected via a 24 hour collection 
in metabolic cages. Urine albumin was measured by ELISA (Albuwell, Exocell Inc., USA). Urine creatinine was 
measured using a picric acid method (Creatinine Companion, Exocell Inc, USA). The HbA1c from a final blood 
collection at time of culling was determined using a DCA Vantage analyzer (Siemens Healthcare, Bayswater, VIC, 
Australia) according to the manufacturer’s instructions.
Histology. Paraffin embedded kidneys sections (2 μm) were stained with Masson’s Trichrome and Periodic 
Acid Schiff (PAS). Assessment of glomerulosclerosis and tubulointerstitial fibrosis was done by two examiners 
independently. Twenty non-overlapping fields were captured under an Olympus photo light microscope linked to 
a Leica DFC 480 digital camera. A semiquantitative glomerulosclerosis index (GSI) score was graded on a scale of 
zero to four (0_normal; 1_involvement of <25% of the glomerulus, 2_ involvement of 25–50% of the glomerulus; 
3_involvement of 50–75% of the glomerulus and 4_totally sclerosed glomeruli)41. The whole kidney average GSI 
score was obtained by averaging scores from all counted glomeruli in one section. For tubulointerstitial scoring 
ten non-overlapping fields were assessed in a similar grading system to the GS score as previously described42. 
Paraffin sections of liver, lung and heart from control and control animals treated for 24 weeks with the LOXL2 
inhibitor were stained with haematoxylin and eosin (HE) and evaluated for structural damage by an independent 
pathologist.
RNA Isolation and Quantitative Real-time RT-PCR. Total RNA was extracted from whole kidney tis-
sue using the RNeasy Plus Mini extraction kit (Qiagen Valencia, CA, USA). cDNA was synthesised using the 
Transcriptor First Strand cDNA synthesis kit (Roche Diagnostics, Mannheim, Germany). Predesigned primers 
(Sigma-Aldrich, NSW Australia) for fibronectin, collagen I and IV, αSMA, E-Cadherin and actin are listed in 
Table 2. Quantitative real-time PCR was performed with SensiMix SYBR hiRox (Bioline, NSW Australia) on the 
AB7900 machine (Applied Biosystems, Australia). Gene expression is presented as fold-change compared with 
control after normalisation to the housekeeping gene actin.
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Immunohistochemistry. Paraffin-embedded kidney sections (4 micron) were dewaxed in xylene and rehy-
drated in graded concentrations of ethanol before heat epitope retrieval in 10 mM citrate buffer, pH6. Endogenous 
peroxidase activity was blocked by incubation in 0.3% hydrogen peroxide. After a 10 min pre-incubation with 
10% protein block (Dako, CA) the sections were incubated overnight at 4 °C with primary antibodies against 
LOXL2 (1:500 dilution, sc-66950, Santa Cruz, USA), fibronectin (dilution 1:1000, ab45688, Abcam, Cambridge, 
UK), collagen I (dilution 1:500, ab34710, Abcam), collagen IV (dilution 1:500, ab6586, Abcam), αSMA (dilu-
tion 1:100, A2547, Sigma Aldrich, USA). The sections were developed with 3,3′-diaminobenzidine chromogen 
(Dako, CA, USA) after incubation with the respective horseradish-peroxidase (HRP) tagged secondary antibod-
ies (Dako) and then counterstained with haematoxilin. The quantification was performed by capturing 10–12 
non-overlapping fields of renal cortex from stained sections at 200× magnification with a Leica microscope 
linked to a DFC 480 digital camera (Leica, Wetzlar, Germany). The percentage of stained area relative to the whole 
area in each field was assessed with image J software (Java-based software program, National Institutes of Health).
Statistical Analysis. Data were analyzed with Prism software V 6.0 (GraphPad, La Jolla, CA) using 
ANOVA with Bonferroni comparison or Mann-Whitney U for non-normally distributed data and expressed as 
mean ± SEM. P-values less than 0.05 were considered to represent statistical significance.
Data Availability. The datasets generated and analysed during the study are available from the correspond-
ing author on reasonable request.
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